The scientific cofounder and chief executive officer of Alloplex Biotherapeutics discussed early data from a phase 1 trial of the PBMC-derived therapy.
“So far, the results have been very interesting... I'm very happy to report that we have 0 drug-related adverse events...the second thing that we noticed is that many of the patients that are in our trial [with] 12 cancers represented in the first 25 patients... at the first measurement, after starting to receive our therapy, the tumors stabilize. They don’t continue to grow. And this is just after 3 doses of our weekly therapy."
SUPLEXA-101, a peripheral blood mononuclear cell (PBMC)-derived activated white blood cell therapy comprised predominantly of natural killer (NK) cells, natural killer T (NKT) cells, γδ T cells, and cytotoxic CD8-positive and CD4-positive T lymphocytes αβ T cells, has demonstrated an excellent safety profile and promising clinical activity across solid and liquid tumor types.
Data from the phase 1 trial (NCT05237206) evaluating SUPLEXA-101 were presented at the World Oncology Cell Therapy Congress (WOCTC) held April 25-26 in Boston, Massachusetts, by Frank Borriello, MD, PhD, scientific cofounder and chief executive officer, Alloplex Biotherapeutics. CGTLive spoke with Borriello to learn more about SUPLEXA-101 and the potential advantages that it may offer across different cancers.
Borriello discussed the manufacturing, cost, and accessibility advantages that the cell therapy offers due to it being a target-agnostic therapy. He also discussed the pharmacodynamics observed in the first treated patients, including white blood cell profiles in these patients being corrected toward normal levels within 2 weeks of administration and a marked decrease in myeloid-derived suppressor cells which are correlated with patient responses. He also hypothesized that using SUPLEXA-101 in combination with other treatment strategies, such as checkpoint inhibitors, may yield more durable and efficacious responses in treating cancers.